AGGRESSIVE NON-HODGKIN LYMPHOMA
Clinical trials for AGGRESSIVE NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new AGGRESSIVE NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a new drug combination (pixantrone plus rituximab, ifosfamide, and etoposide) in 74 adults with aggressive non-Hodgkin lymphoma that had returned or not responded to previous treatments. The goal was to see how well the treatment shrank tumors after two cycles. …
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated May 26, 2026 05:14 UTC
-
New drug combo may reduce deadly transplant complication in blood cancer patients
Disease control CompletedThis study looked at 174 adults with blood cancers who received a stem cell transplant from an unrelated donor. Researchers compared different combinations of immune-suppressing drugs to find the best way to prevent graft-versus-host disease (GVHD), a serious complication where d…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
Triple attack on lymphoma: freeze, vaccinate, and boost immunity
Disease control CompletedThis study tested a new combination treatment for people with non-Hodgkin lymphoma that had come back. The approach used three steps: first, freezing the tumor to kill cancer cells; second, injecting a personalized vaccine made from the patient's own immune cells; and third, givi…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:50 UTC